Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/bmri/volume-2015/242437/figures/242437.fig.004a.svgz" name="242437.fig.004a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>CD147 expression and overall survival</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/bmri/volume-2015/242437/figures/242437.fig.004b.svgz" name="242437.fig.004b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>CD147 expression and disease-free survival</td></tr></table>

<div>Elevated CD147 expression is associated with decreased survival. (a) Elevated CD147 expression in cancer cells is associated with decreased overall survival. (b) Elevated CD147 expression in cancer cells is associated with decreased disease-free survival. CA: carcinoma; TNBC: triple-negative breast cancer; SCC: squamous cell carcinoma; and NSCLC: non-small-cell lung cancer.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis 